多形性胶质母细胞瘤治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

多形性胶质母细胞瘤治疗市场按治疗(化学疗法、放射疗法等)、最终用户和地理区域划分

市场快照

Glioblastoma Multiforme Treatment Market Share
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >8 %
Glioblastoma Multiforme Treatment Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

当异常细胞在脑内形成和生长时,就会发生脑肿瘤。诸如脑部疾病负担增加、主要参与者的强大研发计划以及老年人口不断增加等因素正在推动多形性胶质母细胞瘤治疗市场的增长。根据 Globocan 2018 年的估计,2018 年全球脑癌新病例数为 296,851 例。这导致越来越多的护理提供者转向与胶质母细胞瘤治疗相关的主流治疗。因此,对开发更好的治疗方案的日益关注邀请更多以癌症化疗为基础的公司开发创新药物,并探索不同的地理区域以增加化疗和放射治疗产品的销售,从而推动多形性胶质母细胞瘤治疗市场的增长。

然而,报销问题和严格的监管指南以及与治疗相关的高成本和副作用预计将在预测期内抑制全球市场的增长。

报告范围

根据报告的范围,多形性胶质母细胞瘤 (GBM),也称为胶质母细胞瘤,是最常见的恶性脑肿瘤类型。脑瘤是由大脑中癌细胞的异常生长引起的。在全球范围内,脑肿瘤是导致死亡的主要原因之一。

By Treatment
Chemotherapy
Temozolomide
Bevacizumab
Carmustine
Other Types of Chemotherapy
Radiation Therapy
Other Treatments
By End User
Hospitals/Clinics
Ambulatory Surgical Centers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

化疗板块有望主导市场

根据治疗,市场分为化学疗法、放射疗法等。化疗部分预计将主导市场。导致该部分增长的关键因素是脑癌和其他神经系统癌症的数量不断增加。许多公司正专注于开发用于治疗脑卒中等神经系统疾病的仿制药产品;以及胶质母细胞瘤,以保持其竞争优势并渗透到发达市场和新兴市场的新区域市场。此外,多形性胶质母细胞瘤的管线丰富,预计在此期间将稳步获得 FDA 批准的药物数量。此外,对参与胶质母细胞瘤相关研究的公司的资助预计将提高风险合作伙伴公司的兴趣,

Glioblastoma Multiforme Treatment Market Trends

北美引领多形性胶质母细胞瘤治疗市场

由于资助计划和患者意识的提高,北美领先于多形性胶质母细胞瘤治疗市场,其次是欧洲。根据美国临床肿瘤学会 (ASCO) 的数据,2019 年,预计美国将有 23,820 名成年人(13,410 名男性和 10,410 名女性)被诊断出患有原发性脑和脊髓癌性肿瘤。脑肿瘤占所有原发性中枢神经系统肿瘤的 85% 至 90%。然而,由于对先进治疗方案的认识不断提高,以及该地区新兴经济体的存在,预计亚太地区将以更快的速度增长。

Glioblastoma Multiforme Treatment Market Growth

竞争格局

全球多形性胶质母细胞瘤治疗市场的领先企业有 - Arbor Pharmaceuticals、Bristol-Myers Squibb、Eli Lilly and Company、F. Hoffmann-La Roche Ltd、Merck & Co. Inc.、Sun Pharmaceutical 和 Teva Pharmaceutical Industries Ltd.。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Brain Disorders

      2. 4.2.2 Strong R&D Initiatives from Key Players

      3. 4.2.3 Increasing Aging Population

    3. 4.3 Market Restraints

      1. 4.3.1 Reimbursement Issues and Stringent Regulatory Guidelines

      2. 4.3.2 High Cost and Side Effects Associated with Therapies

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment

      1. 5.1.1 Chemotherapy

        1. 5.1.1.1 Temozolomide

        2. 5.1.1.2 Bevacizumab

        3. 5.1.1.3 Carmustine

        4. 5.1.1.4 Other Types of Chemotherapy

      2. 5.1.2 Radiation Therapy

      3. 5.1.3 Other Treatments

    2. 5.2 By End User

      1. 5.2.1 Hospitals/Clinics

      2. 5.2.2 Ambulatory Surgical Centers

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Arbor Pharmaceuticals, LLC

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Merck & Co. Inc.

      6. 6.1.6 Sun Pharmaceutical Industries Ltd.

      7. 6.1.7 Teva Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Glioblastoma Multiforme Treatment Market market is studied from 2018 - 2026.

The Glioblastoma Multiforme Treatment Market is growing at a CAGR of >8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. are the major companies operating in Glioblastoma Multiforme Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!